All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Regeneron's Libtayo PD-1 inhibitor as adjuvant therapy for cutaneous squamous cell carcinoma treatment
Antibody, cancer, PD-1 inhibitor, cutaneous squamous cell carcinoma, adjuvant therapy - Read more

THE GOOD
Business Development & Partnerships

Sanofi, BenchSci partner on AI-powered preclinical research platform over three years
Research collaboration, AI/ML, drug discovery, R&D, global - Read more

Alpenglow, Virdx partner to develop AI-powered prostate cancer detection tools, financial terms undisclosed
Research collaboration, oncology, AI/ML, diagnostics - Read more

Zenas BioPharma, InnoCare Pharma partner on three autoimmune drugs worth $2+ billion
Licensing deal, autoimmune, multiple sclerosis, milestone payments, China, equity investment - Read more

Boehringer acquires Accent's preclinical cancer small molecule targeting high ISG tumors
Licensing deal, oncology, small molecule, milestone payments - Read more

Legend Biotech, Janssen expand ciltacabtagene autoleucel manufacturing supply agreement globally
Manufacturing agreement, cell therapy, oncology, global - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Sanofi's AlphaMedix hits response rate goals in Ph2 trial for gastroenteropancreatic neuroendocrine tumors
Radioligand therapy, cancer, targeted alpha therapy, neuroendocrine tumors, somatostatin receptor - Read more

Oncoinvent reports positive Ph1 final data for radspherin radium-224 targeting recurrent ovarian cancer
Radiopharmaceutical, cancer, alpha-particle therapy, ovarian cancer, radium-224, peritoneal carcinomatosis - Read more

Hope Medicine reports positive Ph2 results for HMI-115 prolactin receptor blocker in endometriosis, plans Ph3 trials
Antibody, gynecological, monoclonal antibody, endometriosis, prolactin receptor blocker, pain management - Read more

Bavarian Nordic reports positive Ph2 results for MVA-BN mpox vaccine in children aged 2-11 Years
Vaccine, infectious disease, viral vector vaccine, mpox, pediatric population, immunogenicity - Read more

CervoMed reports positive Ph2b data for neflamapimod targeting p38 MAPK in dementia with Lewy bodies
Small molecule, neurological, dementia with Lewy bodies, p38 MAPK inhibitor, neflamapimod, Phase 2b trial - Read more

THE GOOD
Company Launches

Nilo Therapeutics launches with a $101M Series A, brain-immune system drug development targeting the “body-brain circuit”
Autoimmune, neurological, platform technology, preclinical, inflammatory disease - Read more

THE GOOD
Fundraises

ImmunoVec raises $40.7M government grant, polymeric nanoparticles for autoimmune disorders
Cell therapy, autoimmune, gene therapy, platform technology - Read more

Arthrosi raises $153M Series E, developing next-generation gout treatment drug
Gout, small molecule, URAT1 inhibitor, clinical-stage - Read more

Cytiva receives ARPA-H award, developing in vivo CAR-T therapy for solid tumors
Cell therapy, CRISPR, oncology, platform technology, manufacturing - Read more

Apogee Therapeutics raises $300M public offering, clinical-stage inflammatory/immunology biologics
Clinical-stage, biologics, inflammatory, immunology - Read more

Eradivir raises $10M private funding, antiviral therapeutics for influenza/RSV development
Infectious disease, clinical-stage, platform technology, antiviral, bispecific - Read more

Eccogene files Hong Kong IPO, clinical-stage oral GLP-1 obesity drug developer
Clinical-stage, GLP-1, small molecule, obesity - Read more [Paywall]

Karyopharm Therapeutics raises $100M strategic funding, cancer therapy company extending runway
Oncology, small molecule, clinical-stage, hematologic malignancies - Read more

Humacyte raises $60M registered direct offering, commercial-stage bioengineered human tissues
Bioengineered tissues, platform technology, commercial-stage, implantable devices - Read more

Spruce Biosciences raises $50M private placement, neurological disorder therapies development
Neurological, enzyme replacement therapy, rare disease, late-stage - Read more

Esperion raises $75M public offering, commercial-stage non-statin cholesterol medicines
Cardiovascular, small molecule, commercial-stage, oral therapeutics - Read more

THE GOOD
Mergers & Acquisitions

TransCode acquires Polynoma, secures $25M funding to advance phase 3 cancer vaccine but trades majority equity to CK Life Sciences
Cancer vaccine, oncology, strategic, major transaction, financial - Read more

THE GOOD
Politics & Policy

UK government considers raising NICE cost-effectiveness threshold to increase NHS drug spending amid industry pressure
Regulatory, financial, strategic, operational - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Layoffs

Ferring cuts 500 jobs globally as part of reorganization under new enterprise model
Organizational restructuring, operational, cost reduction, strategic - Read more

THE BAD
Market Reports

Cytiva survey shows 51% of biopharma executives cite inconsistent government policies as major obstacle.
Cell and gene therapy, regulatory, strategic, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here